公开(公告)号：EP4223751A1

公开(公告)日：2023-08-09

申请号：EP21874584.2

申请日：2021-09-30

申请人： Humanwell Healthcare (Group) Co., Ltd. ,  Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

发明人： ZHANG, Xuejun ,  ZANG, Yang ,  LI, Xueqiang ,  YANG, Chengbing ,  WANG, Yonggang ,  ZHANG, Bo ,  LI, Yang ,  LIU, Lifei ,  YANG, Jun ,  LI, Lie

IPC分类号： C07D417/12 ,  C07D417/14 ,  A61K31/427 ,  A61K31/506 ,  A61K31/501 ,  A61P25/28 ,  A61P13/08 ,  A61P25/04 ,  A61P13/00 ,  A61P29/00

摘要： Provided are a novel compound that effectively antagonizes P2X3 receptor, a preparation method thereof, and use thereof in the preparation of drugs. The compound is a compound represented by Formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof.

公开(公告)号：EP4116291A1

公开(公告)日：2023-01-11

申请号：EP21765389.8

申请日：2021-03-04

申请人： Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

发明人： ZHANG, Xuejun ,  ZANG, Yang ,  LI, Lie ,  SHEN, Jie ,  LIU, Zhe ,  CHANG, Shaohua ,  WANG, Yonggang

IPC分类号： C07D231/20 ,  A61K31/415 ,  A61P29/00 ,  A61P35/00

摘要： The present disclosure provides a novel compound effective in antagonizing EP4, which is a compound represented by Formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by Formula I:

wherein: R 1 is selected from -CH 3 , -CHF 2 , and -CF 3 ; R 2 is selected from C 2 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 halogen-substituted alkyl, C 3 -C 6 halogen-substituted cycloalkyl; R 3 is selected from hydrogen, halogen, C 1 -C 2 alkyl, C 1 -C 2 fluorine- or chlorine-substituted alkyl; R 4 is selected from hydrogen, halogen, C 1 -C 6 alkyl, C I -C 6 alkoxyl, C 1 -C 6 halogen-substituted alkyl, C 1 -C 6 halogen-substituted alkoxyl.

公开(公告)号：EP3901146A1

公开(公告)日：2021-10-27

申请号：EP19898039.3

申请日：2019-12-17

申请人： Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

发明人： ZHANG, Xuejun ,  LI, Lie ,  SHEN, Jie ,  FU, Qiangqiang ,  WANG, Yonggang

IPC分类号： C07D401/14 ,  C07D403/14 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61P13/10 ,  A61P1/04 ,  A61P11/00 ,  A61P13/00 ,  A61P17/00 ,  A61P19/00 ,  A61P37/00

摘要： Provided is a compound. The compound is a compound represented by formula (A), or a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula (A), where R is

R 1 and R 2 are each independently selected from H, C 1 -C 10 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 10 alkoxyl, halogen, and -CN; and R 3 , R 4 , and R 5 are each independently selected from C 1 -C 10 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 10 alkoxyl, halogen, and -CN, under a premise that: if R 1 is -CH 3 , C1, or - CN, R 2 is not H, and if R 1 is H, R 2 is not H, -CN, or -CH 3 .

公开(公告)号：EP4242204A1

公开(公告)日：2023-09-13

申请号：EP21888667.9

申请日：2021-11-05

申请人： Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

发明人： ZHANG, Xuejun ,  CHANG, Shaohua ,  YE, Dabing ,  LEI, Sijun ,  WANG, Yonggang ,  LIU, Yong ,  SUN, Hongna ,  YANG, Jun ,  LI, Lie

IPC分类号： C07D403/04 ,  A61P35/00 ,  A61K31/513

摘要： The present disclosure provides a novel compound for effectively inhibiting the activity of CD73, a preparation method thereof, and use thereof in the preparation of drugs, and the novel compound is a compound represented by formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof.